ANRO · Alto Neuroscience Inc
United States · RS rating 51 · As of 2026-11-03
| Price | 22.70 USD |
|---|---|
| 1-day change | +2.3% |
| RS rating (overall / 1M / 3M / 12M) | 51 / 44 / 32 / 88 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 36 / 37 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +18.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +38.0% |
| Market cap (USD) | $901.2M |